Immunome Inc. (IMNM)
Immunome Inc. (IMNM) Stock Price, Analysis & Data
| Bid | 19.86 |
| Market Cap | 3.17B |
| Revenue (ttm) | 4.01M |
| Net Income (ttm) | -224.59M |
| Beta | 2.12 |
| EPS (ttm) | -2.53 |
| PE Ratio (ttm) | n/a |
| Forward PE | -13.14 |
| P/B (ttm) | 5.38 |
| P/S (ttm) | 789.51 |
| Earnings Date | Nov 5, 2026 |
| Ask | 29.85 |
| Volume | 1,557,235 |
| Avg. Volume (20D) | 1,382,651 |
| Open | 25.23 |
| Previous Close | 26.25 |
| Day's Range | 25.23 - 28.04 |
| 52-Week Range | 8.66 - 28.04 |
| Analyst | Strong Buy |
| Price Target | 36 (28.62%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About IMNM
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjug...
Financial Performance
In 2025, Immunome's revenue was 6.94M, a decrease of -23.23% compared to the previous year's 9.04M. Earnings were -212.39M, a decrease of -27.5%.
Financial StatementsAnalyst Forecast
According to 13 analyst ratings, the average rating for IMNM stock is "Strong Buy". The 12-month stock price forecast is 36, which is upside of 28.62% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
